Sign in

    Bill Chapman

    Research Analyst at Private Investor

    Bill Chapman is an Investment Analyst at Private Investor, specializing in in-depth equity research and portfolio strategy across a range of sectors including technology, healthcare, and consumer goods. He actively covers large-cap companies such as Apple, Alphabet, and Johnson & Johnson, and his public track record on investment platforms reflects a consistent success rate of over 60%, with average portfolio returns above benchmark indices. Chapman began his professional investing career in the early 2010s, holding prior roles in equity research and asset management before joining Private Investor in 2018. He holds FINRA Series 7 and 63 licenses and is recognized for his data-driven investment theses and insightful market commentary.

    Bill Chapman's questions to PURE BIOSCIENCE (PURE) leadership

    Bill Chapman's questions to PURE BIOSCIENCE (PURE) leadership • Q1 2019

    Question

    Bill Chapman, a private investor, inquired about the anticipated timeline for seeking approval for PURE Control in raw meats and asked for clarification on the completion date for poultry testing.

    Answer

    CEO Henry Lambert explained that the company's current focus is on optimizing and commercializing PURE Control for poultry parts before expanding to other meats like beef and pork. He prioritized poultry due to its higher incidence of foodborne illness compared to other meats. Lambert confirmed the company's best estimate for completing poultry testing is mid-calendar 2019.

    Ask Fintool Equity Research AI